Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Refined ghrelin mimetic — stronger GH release than GHRP-6 with less hunger.
Peptide B
Growth Hormone
Selective growth hormone secretagogue with minimal side effects.
Typical vial
5 mg
Typical dose
100 mcg
Half-life
~15-60 minutes
FDA status
Not FDA approved for any indication.
Typical vial
5 mg
Typical dose
100-300 mcg
Half-life
~2 hours
FDA status
Not FDA approved for human use. Clinical development discont…
GHRP-2 effects
Ipamorelin effects
GHRP-2 side effects
Ipamorelin side effects
GHRP-2 dosing ranges
GH optimization / anti-aging
100 mcg · Two to three times daily (SubQ) · 8-12 weeks
Combined with CJC-1295 (Mod GRF)
100 mcg of each · Two to three times daily · 8-12 weeks
Adult GHD diagnostic (Japan, clinical)
100 mcg IV bolus · Single dose · One-time test
Ipamorelin dosing ranges
GH optimization and anti-aging
100-300 mcg · Two to three times daily (SubQ) · 8-12 weeks
Combined with CJC-1295 (Mod GRF)
100-200 mcg · Two to three times daily · 8-12 weeks
GHRP-2: Refined ghrelin mimetic — stronger GH release than GHRP-6 with less hunger. Typical dose 100 mcg. Ipamorelin: Selective growth hormone secretagogue with minimal side effects. Typical dose 100-300 mcg. Both fall under the Growth Hormone category.
Stacking GHRP-2 with Ipamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
GHRP-2 is typically dosed: Two to three times daily (SubQ) for GH optimization / anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF); Single dose for Adult GHD diagnostic (Japan, clinical). Ipamorelin is typically dosed: Two to three times daily (SubQ) for GH optimization and anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF).
GHRP-2: Not FDA approved for any indication. Ipamorelin: Not FDA approved for human use. Clinical development discontinued by Novo Nordisk.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free